BR112022000936A2 - Inibidores de enzimas - Google Patents

Inibidores de enzimas

Info

Publication number
BR112022000936A2
BR112022000936A2 BR112022000936A BR112022000936A BR112022000936A2 BR 112022000936 A2 BR112022000936 A2 BR 112022000936A2 BR 112022000936 A BR112022000936 A BR 112022000936A BR 112022000936 A BR112022000936 A BR 112022000936A BR 112022000936 A2 BR112022000936 A2 BR 112022000936A2
Authority
BR
Brazil
Prior art keywords
enzyme inhibitors
compounds
therapy
compositions
formula
Prior art date
Application number
BR112022000936A
Other languages
English (en)
Inventor
Alessandro Mazzacani
Stela Obara Alicja
Edward Clark David
Michael Evans David
Emanuela Gancia
Joy Edwards Hannah
William Wrigglesworth Joseph
Rachael Pittaway
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of BR112022000936A2 publication Critical patent/BR112022000936A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

inibidores de enzimas. a presente invenção refre-se a compostos de fórmula (i), composições compreendendo tais compostos; o uso de tais compostos em terapia; e métodos de tratamento de pacientes com tais compostos; em que r1, r2, r3, r4, r5, r6, r7, r8, r9 e r10 são como definidos nesta invenção.
BR112022000936A 2019-08-21 2020-02-13 Inibidores de enzimas BR112022000936A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2019/052359 WO2021032936A1 (en) 2019-08-21 2019-08-21 Enzyme inhibitors
PCT/GB2020/050332 WO2021032937A1 (en) 2019-08-21 2020-02-13 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
BR112022000936A2 true BR112022000936A2 (pt) 2022-03-08

Family

ID=67777359

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000936A BR112022000936A2 (pt) 2019-08-21 2020-02-13 Inibidores de enzimas

Country Status (14)

Country Link
US (1) US20220363668A1 (pt)
EP (1) EP4017587A1 (pt)
JP (1) JP2022545158A (pt)
KR (1) KR20220051207A (pt)
CN (1) CN114269430A (pt)
AR (1) AR118085A1 (pt)
AU (1) AU2020333222A1 (pt)
BR (1) BR112022000936A2 (pt)
CA (1) CA3147228A1 (pt)
CO (1) CO2022000266A2 (pt)
IL (1) IL289783A (pt)
MX (1) MX2022002069A (pt)
TW (1) TW202115033A (pt)
WO (2) WO2021032936A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2388138T3 (es) 2003-08-27 2012-10-09 Ophthotech Corporation Terapia de combinación para tratamiento de trastornos neovasculares oculares
CA2829037C (en) 2011-03-09 2022-05-17 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
WO2017123518A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
AU2017269256B2 (en) 2016-05-23 2021-02-25 The Rockefeller University Aminoacylindazole immunomodulators for treatment of autoimmune diseases
EP3541375B1 (en) 2016-11-18 2023-08-23 Merck Sharp & Dohme LLC Factor xiia inhibitors
US11014920B2 (en) 2016-11-18 2021-05-25 Merck Sharp & Dohme Corp. Factor XIIa inhibitors
AU2018375308A1 (en) 2017-11-29 2020-06-25 The Rockefeller University Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases

Also Published As

Publication number Publication date
CN114269430A (zh) 2022-04-01
AU2020333222A1 (en) 2022-02-24
CO2022000266A2 (es) 2022-01-28
EP4017587A1 (en) 2022-06-29
JP2022545158A (ja) 2022-10-26
CA3147228A1 (en) 2021-02-25
MX2022002069A (es) 2022-03-17
TW202115033A (zh) 2021-04-16
KR20220051207A (ko) 2022-04-26
AR118085A1 (es) 2021-09-15
US20220363668A1 (en) 2022-11-17
IL289783A (en) 2022-03-01
WO2021032937A1 (en) 2021-02-25
WO2021032936A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
BR112017010882B8 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
BR112019002610A2 (pt) piridopirimidinonas inibidoras de cdk2/4/6
BR112022000936A2 (pt) Inibidores de enzimas
BR112015016293A2 (pt) derivados de benzilamina
BR112022001054A2 (pt) Inibidores enzimáticos
BR112017024331A2 (pt) composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
BR112022009514A2 (pt) Compostos úteis como inibidores de proteína helios
BR112022001341A2 (pt) Inibidores de enzima
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
BR112013019643A2 (pt) inibidores de alk, uso e composição farmacêutica compreendendo os mesmos
MX2022001151A (es) Inhibidores deuterados de la via mk2 y metodos de uso de los mismos.
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
BR112022001291A2 (pt) Amidas heterobicíclicas como inibidores de cd38
BR112022001390A2 (pt) Inibidores de enzima
BR112017019605A2 (pt) compostos heterocíclicos úteis como inibidores de tnf
BR112015013485A2 (pt) derivados de benzilsulfonamida como moduladores de rorc
PH12015501038A1 (en) Inhibitors of iap
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
BR112018001980A2 (pt) compostos cíclicos úteis como moduladores de tnf alfa
BR112020016929A8 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos
BR112014008616A2 (pt) compostos antivirais
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
MX2020012263A (es) Compuestos antibacterianos.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]